ARTICLE
19 April 2017

FDA Continues Crackdown On Cosmetics Marketing Claims, And Microbead Ban Begins

DL
Davis+Gilbert LLP

Contributor

Davis+Gilbert LLP is a strategically focused, full-service mid-sized law firm of more than 130 lawyers. Founded over a century ago and located in New York City, the firm represents a wide array of clients – ranging from start-ups to some of the world's largest public companies and financial institutions.
Regulating cosmetics continues to be an important priority for the Food and Drug Administration (FDA)...
United States Media, Telecoms, IT, Entertainment
To print this article, all you need is to be registered or login on Mondaq.com.

Regulating cosmetics continues to be an important priority for the Food and Drug Administration (FDA), although it remains to be seen whether the new administration will take a different approach.

The FDA issued 30 warning letters to cosmetics companies in 2016, the most in recent history. The FDA is concerned with cosmetic claims that indicate that a product can affect a structure or function of the human body, or treat, prevent or mitigate a disease or its symptoms, as these claims indicate that a product is a drug rather than a cosmetic. The FDA singled out claims that a product could "promote collagen production," "reduce all types of hyperpigmentation," "lighten the skin," "fade dark spots" and "stimulate cell renewal." The FDA found that these claims rendered the products to be new and unapproved drugs.

In July 2017, the initial provisions of the Microbead-Free Waters Act of 2015 will go into effect. That means that, on July 1st, manufacturers no longer will be able to produce cosmetics containing microbeads within the United States. By January 1, 2018, all cosmetics that contain microbeads will be banned from sale. Microbeads are solid plastic particles that are less than five millimeters in size and are used for the purpose of exfoliating and cleansing. Microbeads are present in hundreds of cosmetic products and do not dissolve when rinsed off, leading to pollution in oceans and lakes.

Key Takeaways

  • It is unclear whether the new administration will impact the FDA's increasingly conservative approach to cosmetics claims.
  • Companies should continue to vet all new product packaging, marketing and websites to ensure compliance with FDA regulations and review existing packaging and claims through a more conservative lens.
  • Companies that have not already done so, should review their product formulations to ensure that they will cease manufacturing cosmetics containing microbeads by July 1, 2017, and should clear current stocks of products containing microbeads by January 1, 2018.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

ARTICLE
19 April 2017

FDA Continues Crackdown On Cosmetics Marketing Claims, And Microbead Ban Begins

United States Media, Telecoms, IT, Entertainment

Contributor

Davis+Gilbert LLP is a strategically focused, full-service mid-sized law firm of more than 130 lawyers. Founded over a century ago and located in New York City, the firm represents a wide array of clients – ranging from start-ups to some of the world's largest public companies and financial institutions.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More